Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

558.87
+13.412.46%
Post-market: 562.994.12+0.74%19:55 EDT
Volume:1.66M
Turnover:920.76M
Market Cap:60.34B
PE:14.17
High:583.28
Open:583.01
Low:542.89
Close:545.46
Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
14 Jun

Press Release: 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Dow Jones
·
14 Jun

BRIEF-23Andme Reaches Agreement For Sale Of Business To TTAM Research Institute

Reuters
·
14 Jun

23andMe's founder Anne Wojcicki wins bid for DNA testing firm

Reuters
·
14 Jun

Citi Remains a Buy on Regeneron (REGN)

TIPRANKS
·
10 Jun

Regeneron Pharmaceuticals Inc. Stock Advances 4.9%, Outperforms Competitors

Dow Jones
·
10 Jun

JPMorgan cuts Regeneron target, says selloff ‘very much overdone’

TIPRANKS
·
09 Jun

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $800 From $950, Maintains Overweight Rating

MT Newswires Live
·
09 Jun

Regeneron, Sanofi Say Atopic Dermatitis Trial Shows Improvement in Disease Severity

MT Newswires Live
·
09 Jun

U.S. RESEARCH ROUNDUP-Intuitive Surgical, Oracle, Regeneron Pharmaceuticals

Reuters
·
09 Jun

Regeneron, Sanofi presents results from DISCOVER Phase 4 trial of Dupixent

TIPRANKS
·
08 Jun

Regeneron Pharmaceuticals Announces Positive Results from Dupixent Trial in Atopic Dermatitis Patients with Skin of Color at RAD Conference

Reuters
·
08 Jun

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
07 Jun

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial -- Barrons.com

Dow Jones
·
06 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle

Reuters
·
06 Jun

BUZZ-UBS cuts Regeneron PT amid lung disease drug trial setback

Reuters
·
05 Jun

UBS Adjusts Regeneron Pharmaceuticals Price Target to $560 From $633, Maintains Neutral Rating

MT Newswires Live
·
05 Jun

Regeneron Pharma Is Maintained at Neutral by UBS

Dow Jones
·
05 Jun

MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer

Reuters
·
05 Jun

23andMe seeks new bids after $305 million offer from its co-founder

Reuters
·
05 Jun